QR Pharma, Inc., a Radnor, Pennsylvania-based specialty pharmaceutical company focused on developing novel therapeutics for the treatment of Alzheimer’s disease, raised $500,000 in seed financing.Investors include BioAdvance and undisclosed business angels.
These commitments closed a total of $2.4m seed round, which QR opened a year ago, including Ben Franklin Technology Partner’s $500,000 investment as well as other private investor funds.
The capital infusion will further allow the clinical development of two lines of compounds, Posiphen® and Bisnorcymserine (BNC) to treat Alzheimer’s disease (AD) and cognitive impairment.
FinSMEs
02/06/2010